Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6147 participants.
Also called NCT02525939
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 6,147 participants
- Registry
-
NCT02525939
-
- Other papers using this trial's data
- Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02525939. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2021-10 (actual). Results posted on 2022-10-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
- Acronym
- dal-GenE
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- dalcetrapib
- Intervention (Drug)
- Placebo
- Lead sponsor
- DalCor Pharmaceuticals
- Collaborator
- The Montreal Health Innovations Coordinating Center (MHICC)
- Collaborator
- Medpace, Inc.
- Collaborator
- Roche Molecular Systems, Inc
Record details
- Record id
cardio:ct-nct02525939- Content hash
43990e8b2ef053b4d41784c2b1b33470be7c138ae8908f3e9753311650b84a6f